MORE►
Animal Capital
Ben Lamm at the Colossal Lab in Dallas. [Photo: Colossal Biosciences]
Dallas’ Colossal Biosciences Becomes Texas’ First Decacorn, Securing $10.2B Valuation With Series C Funding
by Quincy Preston | Jan 15, 2025
Best known for its moonshot mission to revive the woolly mammoth, Colossal Biosciences has secured $200 million in Series C funding led by TWG Global. The world's first de-extinction company, founded in 2021 by entrepreneur Ben Lamm and renowned Harvard geneticist George Church, Colossal Biosciences is working to restore Earth's lost biodiversity, "making science fiction into science fact."
by David Seeley |
Jan 31, 2023
Colossal says its efforts could help boost "the U.S. high-tech advantage." Its gene editing technologies "will make waves across sectors—in agriculture with new biofuels and preserving biodiversity, as well as in human health through improved gene therapy and vaccine development," the company said.
MORE►
by Quincy Preston and David Seeley |
Mar 9, 2022
Colossal launched last September with a plan to "de-extinct" the woolly mammoth by using CRISPR genetic engineering to create a mammoth-elephant hybrid.
With a total raise of $75 million to date, the startup aims to
have its first set of mammoth-elephant hybrid calves "in 4 to 6 years," co-founder and CEO Ben Lamm told us. But Colossal's goals extend much further—with the potential "to advance human health, enhance food production, reduce environmental impact, and optimize animal health and welfare."
MORE►
